Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials
SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we report safety and immunogenicity from phase I and IIa clinical trials using two-doses of SOBERANA 02 and three-doses (homologous) or heterologous (wi...
Saved in:
| Published in | Vaccine Vol. 40; no. 31; pp. 4220 - 4230 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Ltd
29.07.2022
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0264-410X 1873-2518 1873-2518 |
| DOI | 10.1016/j.vaccine.2022.05.082 |
Cover
| Abstract | SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we report safety and immunogenicity from phase I and IIa clinical trials using two-doses of SOBERANA 02 and three-doses (homologous) or heterologous (with SOBERANA Plus) protocols.
We performed an open-label, sequential and adaptive phase I to evaluate safety and explore the immunogenicity of SOBERANA 02 in two formulations (15 or 25 μg RBD-conjugated to 20 μg of TT) in 40 subjects, 19–59-years-old. Phase IIa was open-label including 100 volunteers 19–80-years, receiving two doses of SOBERANA 02–25 μg. In both trials, half of volunteers were selected to receive a third dose of the corresponding SOBERANA 02 and half received a heterologous dose of SOBERANA Plus. Primary outcome was safety. The secondary outcome was immunogenicity evaluated by anti-RBD IgG ELISA, molecular neutralization of RBD:hACE2 interaction, live-virus-neutralization and specific T-cells response.
The most frequent adverse event (AE) was local pain, other AEs had frequencies ≤ 5%. No serious related-AEs were reported. Phase IIa confirmed the safety in 60 to 80-years-old subjects.
In phase-I SOBERANA 02–25 µg elicited higher immune response than SOBERANA 02–15 µg and progressed to phase IIa. Phase IIa results confirmed the immunogenicity of SOBERANA 02–25 µg even in 60–80-years. Two doses of SOBERANA02-25 µg elicited an immune response similar to that of the Cuban Convalescent Serum Panel and it was higher after the homologous and heterologous third doses. The heterologous scheme showed a higher immunological response. Anti-RBD IgG neutralized the delta variant in molecular assay, with a 2.5-fold reduction compared to D614G neutralization.
SOBERANA 02 was safe and immunogenic in persons aged 19–80 years, eliciting neutralizing antibodies and specific T-cell response. Highest immune responses were obtained in the heterologous three doses protocol.
Trial registry: https://rpcec.sld.cu/trials/RPCEC00000340, https://rpcec.sld.cu/trials/RPCEC00000347 |
|---|---|
| AbstractList | SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we report safety and immunogenicity from phase I and IIa clinical trials using two-doses of SOBERANA 02 and three-doses (homologous) or heterologous (with SOBERANA Plus) protocols.
We performed an open-label, sequential and adaptive phase I to evaluate safety and explore the immunogenicity of SOBERANA 02 in two formulations (15 or 25 μg RBD-conjugated to 20 μg of TT) in 40 subjects, 19–59-years-old. Phase IIa was open-label including 100 volunteers 19–80-years, receiving two doses of SOBERANA 02–25 μg. In both trials, half of volunteers were selected to receive a third dose of the corresponding SOBERANA 02 and half received a heterologous dose of SOBERANA Plus. Primary outcome was safety. The secondary outcome was immunogenicity evaluated by anti-RBD IgG ELISA, molecular neutralization of RBD:hACE2 interaction, live-virus-neutralization and specific T-cells response.
The most frequent adverse event (AE) was local pain, other AEs had frequencies ≤ 5%. No serious related-AEs were reported. Phase IIa confirmed the safety in 60 to 80-years-old subjects.
In phase-I SOBERANA 02–25 µg elicited higher immune response than SOBERANA 02–15 µg and progressed to phase IIa. Phase IIa results confirmed the immunogenicity of SOBERANA 02–25 µg even in 60–80-years. Two doses of SOBERANA02-25 µg elicited an immune response similar to that of the Cuban Convalescent Serum Panel and it was higher after the homologous and heterologous third doses. The heterologous scheme showed a higher immunological response. Anti-RBD IgG neutralized the delta variant in molecular assay, with a 2.5-fold reduction compared to D614G neutralization.
SOBERANA 02 was safe and immunogenic in persons aged 19–80 years, eliciting neutralizing antibodies and specific T-cell response. Highest immune responses were obtained in the heterologous three doses protocol.
Trial registry: https://rpcec.sld.cu/trials/RPCEC00000340, https://rpcec.sld.cu/trials/RPCEC00000347 SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we report safety and immunogenicity from phase I and IIa clinical trials using two-doses of SOBERANA 02 and three-doses (homologous) or heterologous (with SOBERANA Plus) protocols. We performed an open-label, sequential and adaptive phase I to evaluate safety and explore the immunogenicity of SOBERANA 02 in two formulations (15 or 25 μg RBD-conjugated to 20 μg of TT) in 40 subjects, 19-59-years-old. Phase IIa was open-label including 100 volunteers 19-80-years, receiving two doses of SOBERANA 02-25 μg. In both trials, half of volunteers were selected to receive a third dose of the corresponding SOBERANA 02 and half received a heterologous dose of SOBERANA Plus. Primary outcome was safety. The secondary outcome was immunogenicity evaluated by anti-RBD IgG ELISA, molecular neutralization of RBD:hACE2 interaction, live-virus-neutralization and specific T-cells response. The most frequent adverse event (AE) was local pain, other AEs had frequencies ≤ 5%. No serious related-AEs were reported. Phase IIa confirmed the safety in 60 to 80-years-old subjects. In phase-I SOBERANA 02-25 µg elicited higher immune response than SOBERANA 02-15 µg and progressed to phase IIa. Phase IIa results confirmed the immunogenicity of SOBERANA 02-25 µg even in 60-80-years. Two doses of SOBERANA02-25 µg elicited an immune response similar to that of the Cuban Convalescent Serum Panel and it was higher after the homologous and heterologous third doses. The heterologous scheme showed a higher immunological response. Anti-RBD IgG neutralized the delta variant in molecular assay, with a 2.5-fold reduction compared to D614G neutralization. SOBERANA 02 was safe and immunogenic in persons aged 19-80 years, eliciting neutralizing antibodies and specific T-cell response. Highest immune responses were obtained in the heterologous three doses protocol. https://rpcec.sld.cu/trials/RPCEC00000340, https://rpcec.sld.cu/trials/RPCEC00000347. BackgroundSOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we report safety and immunogenicity from phase I and IIa clinical trials using two-doses of SOBERANA 02 and three-doses (homologous) or heterologous (with SOBERANA Plus) protocols.MethodWe performed an open-label, sequential and adaptive phase I to evaluate safety and explore the immunogenicity of SOBERANA 02 in two formulations (15 or 25 μg RBD-conjugated to 20 μg of TT) in 40 subjects, 19–59-years-old. Phase IIa was open-label including 100 volunteers 19–80-years, receiving two doses of SOBERANA 02–25 μg. In both trials, half of volunteers were selected to receive a third dose of the corresponding SOBERANA 02 and half received a heterologous dose of SOBERANA Plus. Primary outcome was safety. The secondary outcome was immunogenicity evaluated by anti-RBD IgG ELISA, molecular neutralization of RBD:hACE2 interaction, live-virus-neutralization and specific T-cells response.ResultsThe most frequent adverse event (AE) was local pain, other AEs had frequencies ≤ 5%. No serious related-AEs were reported. Phase IIa confirmed the safety in 60 to 80-years-old subjects.In phase-I SOBERANA 02–25 µg elicited higher immune response than SOBERANA 02–15 µg and progressed to phase IIa. Phase IIa results confirmed the immunogenicity of SOBERANA 02–25 µg even in 60–80-years. Two doses of SOBERANA02-25 µg elicited an immune response similar to that of the Cuban Convalescent Serum Panel and it was higher after the homologous and heterologous third doses. The heterologous scheme showed a higher immunological response. Anti-RBD IgG neutralized the delta variant in molecular assay, with a 2.5-fold reduction compared to D614G neutralization.ConclusionsSOBERANA 02 was safe and immunogenic in persons aged 19–80 years, eliciting neutralizing antibodies and specific T-cell response. Highest immune responses were obtained in the heterologous three doses protocol.Trial registry: https://rpcec.sld.cu/trials/RPCEC00000340, https://rpcec.sld.cu/trials/RPCEC00000347 SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we report safety and immunogenicity from phase I and IIa clinical trials using two-doses of SOBERANA 02 and three-doses (homologous) or heterologous (with SOBERANA Plus) protocols.BACKGROUNDSOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we report safety and immunogenicity from phase I and IIa clinical trials using two-doses of SOBERANA 02 and three-doses (homologous) or heterologous (with SOBERANA Plus) protocols.We performed an open-label, sequential and adaptive phase I to evaluate safety and explore the immunogenicity of SOBERANA 02 in two formulations (15 or 25 μg RBD-conjugated to 20 μg of TT) in 40 subjects, 19-59-years-old. Phase IIa was open-label including 100 volunteers 19-80-years, receiving two doses of SOBERANA 02-25 μg. In both trials, half of volunteers were selected to receive a third dose of the corresponding SOBERANA 02 and half received a heterologous dose of SOBERANA Plus. Primary outcome was safety. The secondary outcome was immunogenicity evaluated by anti-RBD IgG ELISA, molecular neutralization of RBD:hACE2 interaction, live-virus-neutralization and specific T-cells response.METHODWe performed an open-label, sequential and adaptive phase I to evaluate safety and explore the immunogenicity of SOBERANA 02 in two formulations (15 or 25 μg RBD-conjugated to 20 μg of TT) in 40 subjects, 19-59-years-old. Phase IIa was open-label including 100 volunteers 19-80-years, receiving two doses of SOBERANA 02-25 μg. In both trials, half of volunteers were selected to receive a third dose of the corresponding SOBERANA 02 and half received a heterologous dose of SOBERANA Plus. Primary outcome was safety. The secondary outcome was immunogenicity evaluated by anti-RBD IgG ELISA, molecular neutralization of RBD:hACE2 interaction, live-virus-neutralization and specific T-cells response.The most frequent adverse event (AE) was local pain, other AEs had frequencies ≤ 5%. No serious related-AEs were reported. Phase IIa confirmed the safety in 60 to 80-years-old subjects. In phase-I SOBERANA 02-25 µg elicited higher immune response than SOBERANA 02-15 µg and progressed to phase IIa. Phase IIa results confirmed the immunogenicity of SOBERANA 02-25 µg even in 60-80-years. Two doses of SOBERANA02-25 µg elicited an immune response similar to that of the Cuban Convalescent Serum Panel and it was higher after the homologous and heterologous third doses. The heterologous scheme showed a higher immunological response. Anti-RBD IgG neutralized the delta variant in molecular assay, with a 2.5-fold reduction compared to D614G neutralization.RESULTSThe most frequent adverse event (AE) was local pain, other AEs had frequencies ≤ 5%. No serious related-AEs were reported. Phase IIa confirmed the safety in 60 to 80-years-old subjects. In phase-I SOBERANA 02-25 µg elicited higher immune response than SOBERANA 02-15 µg and progressed to phase IIa. Phase IIa results confirmed the immunogenicity of SOBERANA 02-25 µg even in 60-80-years. Two doses of SOBERANA02-25 µg elicited an immune response similar to that of the Cuban Convalescent Serum Panel and it was higher after the homologous and heterologous third doses. The heterologous scheme showed a higher immunological response. Anti-RBD IgG neutralized the delta variant in molecular assay, with a 2.5-fold reduction compared to D614G neutralization.SOBERANA 02 was safe and immunogenic in persons aged 19-80 years, eliciting neutralizing antibodies and specific T-cell response. Highest immune responses were obtained in the heterologous three doses protocol.CONCLUSIONSSOBERANA 02 was safe and immunogenic in persons aged 19-80 years, eliciting neutralizing antibodies and specific T-cell response. Highest immune responses were obtained in the heterologous three doses protocol.https://rpcec.sld.cu/trials/RPCEC00000340, https://rpcec.sld.cu/trials/RPCEC00000347.TRIAL REGISTRYhttps://rpcec.sld.cu/trials/RPCEC00000340, https://rpcec.sld.cu/trials/RPCEC00000347. SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we report safety and immunogenicity from phase I and IIa clinical trials using two-doses of SOBERANA 02 and three-doses (homologous) or heterologous (with SOBERANA Plus) protocols. We performed an open-label, sequential and adaptive phase I to evaluate safety and explore the immunogenicity of SOBERANA 02 in two formulations (15 or 25 μg RBD-conjugated to 20 μg of TT) in 40 subjects, 19–59-years-old. Phase IIa was open-label including 100 volunteers 19–80-years, receiving two doses of SOBERANA 02–25 μg. In both trials, half of volunteers were selected to receive a third dose of the corresponding SOBERANA 02 and half received a heterologous dose of SOBERANA Plus. Primary outcome was safety. The secondary outcome was immunogenicity evaluated by anti-RBD IgG ELISA, molecular neutralization of RBD:hACE2 interaction, live-virus-neutralization and specific T-cells response. The most frequent adverse event (AE) was local pain, other AEs had frequencies ≤ 5%. No serious related-AEs were reported. Phase IIa confirmed the safety in 60 to 80-years-old subjects. In phase-I SOBERANA 02–25 µg elicited higher immune response than SOBERANA 02–15 µg and progressed to phase IIa. Phase IIa results confirmed the immunogenicity of SOBERANA 02–25 µg even in 60–80-years. Two doses of SOBERANA02-25 µg elicited an immune response similar to that of the Cuban Convalescent Serum Panel and it was higher after the homologous and heterologous third doses. The heterologous scheme showed a higher immunological response. Anti-RBD IgG neutralized the delta variant in molecular assay, with a 2.5-fold reduction compared to D614G neutralization. SOBERANA 02 was safe and immunogenic in persons aged 19–80 years, eliciting neutralizing antibodies and specific T-cell response. Highest immune responses were obtained in the heterologous three doses protocol. Trial registry: https://rpcec.sld.cu/trials/RPCEC00000340, https://rpcec.sld.cu/trials/RPCEC00000347 AbstractBackgroundSOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we report safety and immunogenicity from phase I and IIa clinical trials using two-doses of SOBERANA 02 and three-doses (homologous) or heterologous (with SOBERANA Plus) protocols. MethodWe performed an open-label, sequential and adaptive phase I to evaluate safety and explore the immunogenicity of SOBERANA 02 in two formulations (15 or 25 μg RBD-conjugated to 20 μg of TT) in 40 subjects, 19–59-years-old. Phase IIa was open-label including 100 volunteers 19–80-years, receiving two doses of SOBERANA 02–25 μg. In both trials, half of volunteers were selected to receive a third dose of the corresponding SOBERANA 02 and half received a heterologous dose of SOBERANA Plus. Primary outcome was safety. The secondary outcome was immunogenicity evaluated by anti-RBD IgG ELISA, molecular neutralization of RBD:hACE2 interaction, live-virus-neutralization and specific T-cells response. ResultsThe most frequent adverse event (AE) was local pain, other AEs had frequencies ≤ 5%. No serious related-AEs were reported. Phase IIa confirmed the safety in 60 to 80-years-old subjects. In phase-I SOBERANA 02–25 µg elicited higher immune response than SOBERANA 02–15 µg and progressed to phase IIa. Phase IIa results confirmed the immunogenicity of SOBERANA 02–25 µg even in 60–80-years. Two doses of SOBERANA02-25 µg elicited an immune response similar to that of the Cuban Convalescent Serum Panel and it was higher after the homologous and heterologous third doses. The heterologous scheme showed a higher immunological response. Anti-RBD IgG neutralized the delta variant in molecular assay, with a 2.5-fold reduction compared to D614G neutralization. ConclusionsSOBERANA 02 was safe and immunogenic in persons aged 19–80 years, eliciting neutralizing antibodies and specific T-cell response. Highest immune responses were obtained in the heterologous three doses protocol. Trial registry: https://rpcec.sld.cu/trials/RPCEC00000340, https://rpcec.sld.cu/trials/RPCEC00000347 |
| Author | Cruz-Sui, Otto Teresa Pérez-Guevara, María Espi Ávila, Jennifer Ontivero-Pino, Ivis Pérez-Nicado, Rocmira Fraga-Quintero, Anitza González-Mugica, Raul Valera-Fernández, Rodrigo Díaz-Hernández, Marianniz Tundidor, Yaima Quintero Moreno, Lauren Eugenia-Toledo-Romaní, María Verdecia-Sánchez, Leslyhana Muñoz-Morejon, Yaima García-Rivera, Dagmar Ojito-Magaz, Eduardo Gómez-Maceo, Yanet Mendoza-Hernández, Ivis Palenzuela-Díaz, Ariel Sánchez-Ramírez, Belinda Morffi-Cinta, Irania García-Montero, Majela Cardoso-SanJorge, Félix Morales-García, Marilin Pérez-Massón, Beatriz Paredes-Moreno, Beatriz Fernandez-Castillo, Sonsire Fontanies Fernández, Marcos Garrido-Arteaga, Raine Noa-Romero, Enrique Valdés-Balbín, Yury Ramírez Gonzalez, Ubel Guang-Wu-Chen Manuel Coviella-Artime, José Rojas, Gertrudis Santana-Mederos, Darielys Orosa-Vázquez, Ivette Martínez-Pérez, Marisel García-López, Elena Hernández-García, Tays Valenzuela-Silva, Carmen Medina Nápoles, Maite Rivera, Daniel G. Pi-Estopiñán, Franciscary Martínez-Bedoya, Dayle Rodríguez-Noda, Laura |
| Author_xml | – sequence: 1 givenname: María surname: Eugenia-Toledo-Romaní fullname: Eugenia-Toledo-Romaní, María organization: “Pedro Kourí” Tropical Medicine Institute, Av “Novia del Mediodía”, Kv 6 1/2, La Lisa, Habana 11400, Cuba – sequence: 2 givenname: Leslyhana surname: Verdecia-Sánchez fullname: Verdecia-Sánchez, Leslyhana organization: Clinic #1. 21 St. and 190, La Lisa, Habana, Cuba – sequence: 3 givenname: Meiby surname: Rodríguez-González fullname: Rodríguez-González, Meiby organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 4 givenname: Laura surname: Rodríguez-Noda fullname: Rodríguez-Noda, Laura organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 5 givenname: Carmen surname: Valenzuela-Silva fullname: Valenzuela-Silva, Carmen organization: Cybernetics, Mathematics and Physics Institute, 15th Street #55, Vedado, Plaza de la Revolución, La Habana 10400, Cuba – sequence: 6 givenname: Beatriz surname: Paredes-Moreno fullname: Paredes-Moreno, Beatriz organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 7 givenname: Belinda surname: Sánchez-Ramírez fullname: Sánchez-Ramírez, Belinda organization: Centre of Molecular Immunology, 15th Ave. and 216 Street, Siboney, Playa, Havana, Cuba – sequence: 8 givenname: Rocmira surname: Pérez-Nicado fullname: Pérez-Nicado, Rocmira organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 9 givenname: Raul surname: González-Mugica fullname: González-Mugica, Raul organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 10 givenname: Tays surname: Hernández-García fullname: Hernández-García, Tays organization: Centre of Molecular Immunology, 15th Ave. and 216 Street, Siboney, Playa, Havana, Cuba – sequence: 11 givenname: Gretchen surname: Bergado-Baez fullname: Bergado-Baez, Gretchen organization: Centre of Molecular Immunology, 15th Ave. and 216 Street, Siboney, Playa, Havana, Cuba – sequence: 12 givenname: Franciscary surname: Pi-Estopiñán fullname: Pi-Estopiñán, Franciscary organization: Centre of Molecular Immunology, 15th Ave. and 216 Street, Siboney, Playa, Havana, Cuba – sequence: 13 givenname: Otto surname: Cruz-Sui fullname: Cruz-Sui, Otto organization: National Civil Defense Research Laboratory. San José de las Lajas, Mayabeque, Cuba – sequence: 14 givenname: Anitza surname: Fraga-Quintero fullname: Fraga-Quintero, Anitza organization: National Civil Defense Research Laboratory. San José de las Lajas, Mayabeque, Cuba – sequence: 15 givenname: Majela surname: García-Montero fullname: García-Montero, Majela organization: National Civil Defense Research Laboratory. San José de las Lajas, Mayabeque, Cuba – sequence: 16 givenname: Ariel surname: Palenzuela-Díaz fullname: Palenzuela-Díaz, Ariel organization: Centre for Immunoassays, 134 St and 25, Cubanacán, Playa, La Habana 11600, Cuba – sequence: 17 givenname: Gerardo surname: Baró-Román fullname: Baró-Román, Gerardo organization: Centre for Immunoassays, 134 St and 25, Cubanacán, Playa, La Habana 11600, Cuba – sequence: 18 givenname: Ivis surname: Mendoza-Hernández fullname: Mendoza-Hernández, Ivis organization: National Clinical Trials Coordinating Center, 5th Ave and 62, Miramar, Playa, Havana, Cuba – sequence: 19 givenname: Sonsire surname: Fernandez-Castillo fullname: Fernandez-Castillo, Sonsire organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 20 givenname: Yanet surname: Climent-Ruiz fullname: Climent-Ruiz, Yanet organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 21 givenname: Darielys surname: Santana-Mederos fullname: Santana-Mederos, Darielys organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 22 givenname: Ubel surname: Ramírez Gonzalez fullname: Ramírez Gonzalez, Ubel organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 23 givenname: Yanelda surname: García-Vega fullname: García-Vega, Yanelda organization: Centre of Molecular Immunology, 15th Ave. and 216 Street, Siboney, Playa, Havana, Cuba – sequence: 24 givenname: Beatriz surname: Pérez-Massón fullname: Pérez-Massón, Beatriz organization: Centre of Molecular Immunology, 15th Ave. and 216 Street, Siboney, Playa, Havana, Cuba – sequence: 25 surname: Guang-Wu-Chen fullname: Guang-Wu-Chen organization: Chengdu Olisynn Biotech. Co. Ltd., and State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, People’s Republic of China – sequence: 26 givenname: Tammy surname: Boggiano-Ayo fullname: Boggiano-Ayo, Tammy organization: Centre of Molecular Immunology, 15th Ave. and 216 Street, Siboney, Playa, Havana, Cuba – sequence: 27 givenname: Eduardo surname: Ojito-Magaz fullname: Ojito-Magaz, Eduardo organization: Centre of Molecular Immunology, 15th Ave. and 216 Street, Siboney, Playa, Havana, Cuba – sequence: 28 givenname: Daniel G. surname: Rivera fullname: Rivera, Daniel G. organization: Laboratory of Synthetic and Biomolecular Chemistry, Faculty of Chemistry, University of Havana, Havana 10400, Cuba – sequence: 29 givenname: Yury surname: Valdés-Balbín fullname: Valdés-Balbín, Yury organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 30 givenname: Dagmar surname: García-Rivera fullname: García-Rivera, Dagmar email: dagarcia@finlay.edu.cu organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 31 givenname: Vicente surname: Vérez-Bencomo fullname: Vérez-Bencomo, Vicente email: vicente.verez@finlay.edu.cu organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 32 givenname: Yanet surname: Gómez-Maceo fullname: Gómez-Maceo, Yanet organization: Clinic #1. 21 St. and 190, La Lisa, Habana, Cuba – sequence: 33 givenname: Radamet surname: Reyes-Matienzo fullname: Reyes-Matienzo, Radamet organization: Clinic #1. 21 St. and 190, La Lisa, Habana, Cuba – sequence: 34 givenname: José surname: Manuel Coviella-Artime fullname: Manuel Coviella-Artime, José organization: Clinic #1. 21 St. and 190, La Lisa, Habana, Cuba – sequence: 35 givenname: Irania surname: Morffi-Cinta fullname: Morffi-Cinta, Irania organization: Clinic #1. 21 St. and 190, La Lisa, Habana, Cuba – sequence: 36 givenname: Marisel surname: Martínez-Pérez fullname: Martínez-Pérez, Marisel organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 37 givenname: Ismavy surname: Castillo-Quintana fullname: Castillo-Quintana, Ismavy organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 38 givenname: Aniurka surname: Garcés-Hechavarría fullname: Garcés-Hechavarría, Aniurka organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 39 givenname: Rodrigo surname: Valera-Fernández fullname: Valera-Fernández, Rodrigo organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 40 givenname: Dayle surname: Martínez-Bedoya fullname: Martínez-Bedoya, Dayle organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 41 givenname: Raine surname: Garrido-Arteaga fullname: Garrido-Arteaga, Raine organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 42 givenname: Félix surname: Cardoso-SanJorge fullname: Cardoso-SanJorge, Félix organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 43 givenname: Lauren surname: Quintero Moreno fullname: Quintero Moreno, Lauren organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 44 givenname: Ivis surname: Ontivero-Pino fullname: Ontivero-Pino, Ivis organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 45 givenname: María surname: Teresa Pérez-Guevara fullname: Teresa Pérez-Guevara, María organization: Centre of Molecular Immunology, 15th Ave. and 216 Street, Siboney, Playa, Havana, Cuba – sequence: 46 givenname: Marilin surname: Morales-García fullname: Morales-García, Marilin organization: Centre of Molecular Immunology, 15th Ave. and 216 Street, Siboney, Playa, Havana, Cuba – sequence: 47 givenname: Enrique surname: Noa-Romero fullname: Noa-Romero, Enrique organization: Centre of Molecular Immunology, 15th Ave. and 216 Street, Siboney, Playa, Havana, Cuba – sequence: 48 givenname: Ivette surname: Orosa-Vázquez fullname: Orosa-Vázquez, Ivette organization: Centre of Molecular Immunology, 15th Ave. and 216 Street, Siboney, Playa, Havana, Cuba – sequence: 49 givenname: Marianniz surname: Díaz-Hernández fullname: Díaz-Hernández, Marianniz organization: Centre of Molecular Immunology, 15th Ave. and 216 Street, Siboney, Playa, Havana, Cuba – sequence: 50 givenname: Gertrudis surname: Rojas fullname: Rojas, Gertrudis organization: Centre of Molecular Immunology, 15th Ave. and 216 Street, Siboney, Playa, Havana, Cuba – sequence: 51 givenname: Yaima surname: Tundidor fullname: Tundidor, Yaima organization: Centre of Molecular Immunology, 15th Ave. and 216 Street, Siboney, Playa, Havana, Cuba – sequence: 52 givenname: Elena surname: García-López fullname: García-López, Elena organization: National Clinical Trials Coordinating Center, 5th Ave and 62, Miramar, Playa, Havana, Cuba – sequence: 53 givenname: Yaima surname: Muñoz-Morejon fullname: Muñoz-Morejon, Yaima organization: National Clinical Trials Coordinating Center, 5th Ave and 62, Miramar, Playa, Havana, Cuba – sequence: 54 givenname: Evelyn surname: Galano-Frutos fullname: Galano-Frutos, Evelyn organization: National Clinical Trials Coordinating Center, 5th Ave and 62, Miramar, Playa, Havana, Cuba – sequence: 55 givenname: Julián surname: Rodríguez-Alvarez fullname: Rodríguez-Alvarez, Julián organization: National Clinical Trials Coordinating Center, 5th Ave and 62, Miramar, Playa, Havana, Cuba – sequence: 56 givenname: Amaylid surname: Arteaga fullname: Arteaga, Amaylid organization: National Clinical Trials Coordinating Center, 5th Ave and 62, Miramar, Playa, Havana, Cuba – sequence: 57 givenname: Maite surname: Medina Nápoles fullname: Medina Nápoles, Maite organization: National Clinical Trials Coordinating Center, 5th Ave and 62, Miramar, Playa, Havana, Cuba – sequence: 58 givenname: Jennifer surname: Espi Ávila fullname: Espi Ávila, Jennifer organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba – sequence: 59 givenname: Marcos surname: Fontanies Fernández fullname: Fontanies Fernández, Marcos organization: Finlay Vaccine Institute, 21st Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35691871$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNU9uO0zAQjdAitrvwCSBLvPCSMnYuTkALKtUClVZU2gLizXKdSeuS2CVOivol_C4OvQArIfrk2zlnxmdmLoIzYw0GwWMKQwo0fb4abqRS2uCQAWNDSIaQsXvBgGY8CllCs7NgACyNw5jCl_PgwrkVACQRzR8E51GS5h5IB8GPmSyx3RJpCqLrujN2gUYr7a9s6W9bHc5GtzMytp9DRvYhyWz65vp29GFEgBFtyNLWtrIL2zliG7LEFpvD2akl1viCTNdoSCXnWJH1Ujokk18h9_uJJKrSPq6sSNtoWbmHwf3SL_hov14Gn95efxy_D2-m7ybj0U2o0oi3YcIhyXiSJd6DCJVSaZ5DlsO8AJ5TThWLAaNCqpjNZSwLHpVzLOJSIpTZnJbRZZDudDuzltvvsqrEutG1bLaCguidFiux_7bonRaQCO-0J77aEdfdvMZCoWkb-ZtspRZ_vxi9FAu7ETlNeRZRL_BsL9DYbx26VtTaKawqadA7JxinPkxO4xOgKU_yLI4h99Cnd6Ar2zXGW9ij0jyCOAOPevJn8sesD33hAS93ANVY5xoshW8J2Wrb_0VX__UmucM-1dPXOx76im80NsIpjUZhoRtUrSisPrUqR4VDX33FLbqjF1Q4zxGzfkL6AWEMgFMee4GrfwuckMBPqqQiFg |
| CitedBy_id | crossref_primary_10_1001_jamanetworkopen_2023_10302 crossref_primary_10_1016_j_it_2023_01_005 crossref_primary_10_1126_sciadv_adg0330 crossref_primary_10_3390_vaccines11111636 crossref_primary_10_1016_j_jconrel_2024_01_017 crossref_primary_10_3389_fbioe_2023_1287551 crossref_primary_10_1001_jamanetworkopen_2022_53301 crossref_primary_10_3390_vaccines10122086 crossref_primary_10_1016_j_ijbiomac_2024_129284 crossref_primary_10_1016_j_lana_2024_100750 crossref_primary_10_3390_vaccines12030326 crossref_primary_10_3390_vaccines12030243 crossref_primary_10_3390_ijms24021701 crossref_primary_10_1371_journal_ppat_1011744 crossref_primary_10_3390_v15091786 crossref_primary_10_1007_s00281_023_00996_2 crossref_primary_10_1016_j_ijid_2022_11_016 crossref_primary_10_3389_fimmu_2023_1237916 crossref_primary_10_3389_fimmu_2023_1169666 crossref_primary_10_2139_ssrn_4174293 crossref_primary_10_1038_s41598_023_50450_4 crossref_primary_10_1016_j_vaccine_2024_03_034 crossref_primary_10_1089_jir_2023_0141 crossref_primary_10_1016_j_lana_2022_100423 crossref_primary_10_1057_s41292_024_00341_2 crossref_primary_10_3390_vaccines11010117 |
| Cites_doi | 10.1016/S0140-6736(20)31605-6 10.1021/acscentsci.1c00216 10.1056/NEJMoa2027906 10.1038/s41587-020-0631-z 10.1016/S0140-6736(21)01429-X 10.1016/S0140-6736(20)31604-4 10.1126/science.1095209 10.1038/s43587-021-00114-7 10.1038/d41586-021-01762-w 10.1021/acschembio.1c00272 10.1007/978-1-4939-7447-4_30 10.1016/S0140-6736(20)32661-1 10.1038/s41586-020-2639-4 10.1146/annurev-med-042420-113212 10.1016/j.cell.2020.08.017 10.1080/14760584.2021.1976153 10.1038/s41586-021-03777-9 10.1007/978-1-62703-992-5_27 10.1101/2021.06.30.21259439 10.1056/NEJMoa2107659 10.1056/NEJMoa2105290 10.1001/jama.2021.8565 10.1016/j.lana.2021.100079 10.1016/S1473-3099(20)30831-8 10.1016/S0140-6736(20)31208-3 10.1016/j.vaccine.2014.06.094 10.1016/S0140-6736(21)01115-6 10.1038/d41586-021-01359-3 10.1056/NEJMoa2035389 10.1016/S0140-6736(21)01358-1 10.1016/S0140-6736(21)00234-8 10.1056/NEJMoa2034577 10.1126/sciimmunol.abd6160 10.1016/S1473-3099(21)00127-4 10.1056/NEJMoa2101544 10.1046/j.1365-2249.2000.01109.x 10.1002/jmv.25986 |
| ContentType | Journal Article |
| Copyright | 2022 Elsevier Ltd Elsevier Ltd Copyright © 2022 Elsevier Ltd. All rights reserved. 2022. Elsevier Ltd 2022 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd |
| Copyright_xml | – notice: 2022 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2022 Elsevier Ltd. All rights reserved. – notice: 2022. Elsevier Ltd – notice: 2022 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd |
| CorporateAuthor | SOBERANA Research Group |
| CorporateAuthor_xml | – name: SOBERANA Research Group |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 7S9 L.6 5PM ADTOC UNPAY |
| DOI | 10.1016/j.vaccine.2022.05.082 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Journals ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Biological Science Collection Consumer Health Database Health & Medical Collection (Alumni Edition) Healthcare Administration Database Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE Research Library Prep MEDLINE - Academic AGRICOLA |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 4 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-2518 |
| EndPage | 4230 |
| ExternalDocumentID | oai:pubmedcentral.nih.gov:9167831 PMC9167831 35691871 10_1016_j_vaccine_2022_05_082 S0264410X22007174 1_s2_0_S0264410X22007174 |
| Genre | Clinical Trial, Phase II Clinical Trial, Phase I Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Cuba |
| GeographicLocations_xml | – name: Cuba |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ACDAQ ACGFO ACGFS ACIEU ACIUM ACLOT ACMHX ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT ADSLC AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGEKW AGGSO AGUBO AGWPP AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EFLBG EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO Q38 ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- ~HD .GJ 29Q 3V. AACTN AAQXK ABWVN ABXDB ACRPL ADMUD ADNMO ADVLN AFCTW AFJKZ AFKWA AGHFR AHHHB AJOXV ALIPV AMFUW ASPBG AVWKF AZFZN EJD FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ R2- RIG SAE SEW SIN SVS WUQ XPP ZGI ZXP AAIAV ABLVK ABYKQ AESVU LCYCR QYZTP AAYXX AGQPQ CITATION CGR CUY CVF ECM EIF NPM 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 7S9 L.6 5PM ADTOC UNPAY |
| ID | FETCH-LOGICAL-c637t-5705875850223eccc6990890bd079171c240e3dac42ba4ad73fbed4fae0f8b1f3 |
| IEDL.DBID | BENPR |
| ISSN | 0264-410X 1873-2518 |
| IngestDate | Sun Oct 26 04:16:21 EDT 2025 Tue Sep 30 16:56:21 EDT 2025 Sun Sep 28 04:36:29 EDT 2025 Sun Sep 28 06:16:34 EDT 2025 Tue Oct 07 06:45:13 EDT 2025 Wed Feb 19 02:25:46 EST 2025 Thu Apr 24 23:06:52 EDT 2025 Thu Oct 09 00:38:53 EDT 2025 Fri Feb 23 02:40:05 EST 2024 Tue Feb 25 20:03:51 EST 2025 Tue Oct 14 19:30:30 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 31 |
| Keywords | COVID-19 SARS-CoV-2 Heterologous immunization scheme Conjugate vaccine Subunit vaccine |
| Language | English |
| License | Copyright © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c637t-5705875850223eccc6990890bd079171c240e3dac42ba4ad73fbed4fae0f8b1f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://www.ncbi.nlm.nih.gov/pmc/articles/9167831 |
| PMID | 35691871 |
| PQID | 2676930480 |
| PQPubID | 105530 |
| PageCount | 11 |
| ParticipantIDs | unpaywall_primary_10_1016_j_vaccine_2022_05_082 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9167831 proquest_miscellaneous_2718239141 proquest_miscellaneous_2675984409 proquest_journals_2676930480 pubmed_primary_35691871 crossref_citationtrail_10_1016_j_vaccine_2022_05_082 crossref_primary_10_1016_j_vaccine_2022_05_082 elsevier_sciencedirect_doi_10_1016_j_vaccine_2022_05_082 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X22007174 elsevier_clinicalkey_doi_10_1016_j_vaccine_2022_05_082 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-07-29 |
| PublicationDateYYYYMMDD | 2022-07-29 |
| PublicationDate_xml | – month: 07 year: 2022 text: 2022-07-29 day: 29 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands – name: Kidlington |
| PublicationTitle | Vaccine |
| PublicationTitleAlternate | Vaccine |
| PublicationYear | 2022 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Sekine, Perez-Potti, Rivera-Ballesteros, Strålin, Gorin, Olsson (b0235) 2020; 183 Callaway (b0240) 2021; 593 G. Guzman. Updated report of the “Pedro Kouri” Tropical Medicine Institute on the circulating strains of SARS COVID19 in Havana. Personal communication. (Consulted October 20, 2021). Xia, Zhang, Wang, Wang, Yang, Gao (b0185) 2021; 21 Zhu, Guan, Li, Huang, Jiang, Hou (b0175) 2020; 396 Tanriover, Doğanay, Akova, Güner, Azap, Akhan (b0050) 2021; 398 Baden, El Sahly, Essink, Kotloff, Frey, Novak (b0015) 2021; 384 Logunov, Dolzhikova, Shcheblyakov, Tukhvatulin, Zubkova, Dzharullaeva (b0035) 2021; 397 (consulted October 19, 2021). Rojas, Carmenate (b0155) 2018; 1701 Heath, Galiza, Baxter, Boffito, Browne, Burns (b0060) 2021; 385 Valdes-Balbin, Santana-Mederos, Paquet, Fernandez, Climent, Chiodo (b0095) 2021; 7 Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 14. June 3, 2021. Available at Falsey, Sobieszczyk, Hirsch, Sproule, Robb, Corey (b0030) 2021; 385 Folegatti, Ewer, Aley, Angus, Becker, Belij-Rammerstorfer (b0190) 2020; 396 Polack, Thomas, Kitchin, Absalon, Gurtman, Lockhart (b0020) 2020; 383 International Clinical Trials Registry Platform. Identifier RPCEC00000340. phase I study, open, sequential and adaptive for evaluating the safety, reactogenicity and explore the immunogenicity of the prophylactic Vaccine candidate FINLAY-FR-2 anti SARSCoV-2 (COVID-19). Bian, Gao, Gao, Wang, He, Wu (b0210) 2021; 20 Tan, Chia, Qin, Liu, Chen, Tiu (b0145) 2020; 38 Manenti, Maggetti, Casa, Martinuzzi, Torelli, Trombetta (b0160) 2020; 92 . Dotres, Puga, Ricardo, Broño, Paredes, Echemendía (b0090) 2014; 32 Edition. Geneva: WHO; 2018. Yang, Li, Dai, Wang, He, Li (b0135) 2021; 21 Shaw, Stuart, Greenland, Liu, Nguyen Van-Tam, Snape (b0245) 2021; 397 Sheikh, McMenamin, Taylor, Robertson (b0215) 2021; 397 Goldblatt (b0165) 2000; 119 World Health Organization. Causality Assessment of an Adverse Event Following Immunization (AEFI). 2 Voysey, Clemens, Madhi, Weckx, Folegatti, Aley (b0025) 2021; 397 WHO Coronavirus (COVID-19) Dashboard Coronavirus (COVID-19) vaccinations. Guidance for Industry: Development and Licensure of Vaccines to Prevent COVID-19, USFDA, June 2020. International Clinical Trials Registry Platform. Identifier RPCEC00000366. A phase II, sequential, multicenter, adaptive, parallel groups, randomized, placebo-controlled, double-blinded, to evaluate safety, reactogenicity and immunogenicity of the prophylactic vaccine candidate FINLAY-FR-1A anti SARS-CoV-2, in COVID-19 convalescents. (Consulted October 15, 2021). Al Kaabi, Zhang, Xia, Yang, Al Qahtani, Abdulrazzaq (b0045) 2021; 326 Chang-Monteagudo A, Ochoa-Azze R, Climent-Ruiz Y, Macías-Abraham C, Rodríguez-Noda L, Valenzuela-Silva C et al. A single dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD recombinant vaccine enhances neutralization response in COVID-19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial. Lancet Reg Health Am 2021;4:100079. Logunov, Dolzhikova, Shcheblyakov, Tukhvatulin, Zubkova, Dzharullaeva (b0140) 2021; 397 Hotez, Bottazzi (b0080) 2022; 73 Sadoff, Gray, Vandebosch, Cárdenas, Shukarev, Grinsztejn (b0040) 2021; 384 Mulligan, Lyke, Kitchin, Absalon, Gurtman, Lockhart (b0170) 2020; 586 Rojas (b0150) 2014; 1131 Walsh, Frenck, Falsey, Kitchin, Absalon, Gurtman (b0195) 2020; 383 Common Terminology Criteria for Adverse Events (CTCAE): Available Verez-Bencomo, Fernández-Santana, Hardy, Toledo, Rodríguez, Heynngnezz (b0085) 2004; 305 Valdes-Balbin, Santana-Mederos, Quintero, Fernandez, Rodriguez, Sanchez-Ramírez (b0100) 2021; 16 Altmann, Boyton (b0230) 2020; 5 Planas, Veyer, Baidaliuk, Staropoli, Guivel-Benhassine, Rajah (b0225) 2021; 596 Padma (b0070) 2021; 595 Zhu, Li, Guan, Hou, Wang, Li (b0180) 2020; 395 COVID-19 – Landscape of novel coronavirus candidate vaccine development worldwide, September 17, 2021. Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial. medRxiv International Clinical Trials Registry Platform. Identifier RPCEC00000347 phase II study, multicenter and adaptive for evaluating the immunogenicity, safety and reactogenicity of the Anti-SARS Prophylactic Vaccine Candidate - CoV - 2, FINLAY- FR-2 (COVID-19). Bartleson, Radenkovic, Covarrubias, Furman, Winer, Verdin (b0200) 2021; 1 Heath (10.1016/j.vaccine.2022.05.082_b0060) 2021; 385 Folegatti (10.1016/j.vaccine.2022.05.082_b0190) 2020; 396 Valdes-Balbin (10.1016/j.vaccine.2022.05.082_b0100) 2021; 16 10.1016/j.vaccine.2022.05.082_b0120 10.1016/j.vaccine.2022.05.082_b0125 10.1016/j.vaccine.2022.05.082_b0115 Walsh (10.1016/j.vaccine.2022.05.082_b0195) 2020; 383 Tanriover (10.1016/j.vaccine.2022.05.082_b0050) 2021; 398 Sheikh (10.1016/j.vaccine.2022.05.082_b0215) 2021; 397 Planas (10.1016/j.vaccine.2022.05.082_b0225) 2021; 596 Padma (10.1016/j.vaccine.2022.05.082_b0070) 2021; 595 Bian (10.1016/j.vaccine.2022.05.082_b0210) 2021; 20 10.1016/j.vaccine.2022.05.082_b0075 Rojas (10.1016/j.vaccine.2022.05.082_b0150) 2014; 1131 Sadoff (10.1016/j.vaccine.2022.05.082_b0040) 2021; 384 10.1016/j.vaccine.2022.05.082_b0110 Callaway (10.1016/j.vaccine.2022.05.082_b0240) 2021; 593 10.1016/j.vaccine.2022.05.082_b0105 Tan (10.1016/j.vaccine.2022.05.082_b0145) 2020; 38 Xia (10.1016/j.vaccine.2022.05.082_b0185) 2021; 21 Zhu (10.1016/j.vaccine.2022.05.082_b0180) 2020; 395 Voysey (10.1016/j.vaccine.2022.05.082_b0025) 2021; 397 Verez-Bencomo (10.1016/j.vaccine.2022.05.082_b0085) 2004; 305 10.1016/j.vaccine.2022.05.082_b0220 10.1016/j.vaccine.2022.05.082_b0065 Polack (10.1016/j.vaccine.2022.05.082_b0020) 2020; 383 Al Kaabi (10.1016/j.vaccine.2022.05.082_b0045) 2021; 326 Manenti (10.1016/j.vaccine.2022.05.082_b0160) 2020; 92 Altmann (10.1016/j.vaccine.2022.05.082_b0230) 2020; 5 Logunov (10.1016/j.vaccine.2022.05.082_b0035) 2021; 397 Hotez (10.1016/j.vaccine.2022.05.082_b0080) 2022; 73 Valdes-Balbin (10.1016/j.vaccine.2022.05.082_b0095) 2021; 7 Goldblatt (10.1016/j.vaccine.2022.05.082_b0165) 2000; 119 Baden (10.1016/j.vaccine.2022.05.082_b0015) 2021; 384 Dotres (10.1016/j.vaccine.2022.05.082_b0090) 2014; 32 Yang (10.1016/j.vaccine.2022.05.082_b0135) 2021; 21 Falsey (10.1016/j.vaccine.2022.05.082_b0030) 2021; 385 Zhu (10.1016/j.vaccine.2022.05.082_b0175) 2020; 396 10.1016/j.vaccine.2022.05.082_b0130 10.1016/j.vaccine.2022.05.082_b0055 10.1016/j.vaccine.2022.05.082_b0010 Bartleson (10.1016/j.vaccine.2022.05.082_b0200) 2021; 1 10.1016/j.vaccine.2022.05.082_b0005 Mulligan (10.1016/j.vaccine.2022.05.082_b0170) 2020; 586 10.1016/j.vaccine.2022.05.082_b0205 Logunov (10.1016/j.vaccine.2022.05.082_b0140) 2021; 397 Shaw (10.1016/j.vaccine.2022.05.082_b0245) 2021; 397 Rojas (10.1016/j.vaccine.2022.05.082_b0155) 2018; 1701 Sekine (10.1016/j.vaccine.2022.05.082_b0235) 2020; 183 |
| References_xml | – reference: Edition. Geneva: WHO; 2018. – volume: 92 start-page: 2096 year: 2020 end-page: 2104 ident: b0160 article-title: Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples publication-title: J Med Virol – reference: WHO Coronavirus (COVID-19) Dashboard, – reference: (consulted October 19, 2021). – volume: 385 start-page: 2348 year: 2021 end-page: 2360 ident: b0030 article-title: Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine publication-title: N Engl J Med – volume: 183 start-page: 158 year: 2020 end-page: 168.e14 ident: b0235 article-title: Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19 publication-title: Cell – volume: 397 start-page: 671 year: 2021 end-page: 681 ident: b0140 article-title: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia publication-title: Lancet – volume: 1701 start-page: 535 year: 2018 end-page: 560 ident: b0155 article-title: Phagekines: screening binding properties and biological activity of functional cytokines displayed on phages publication-title: Methods Mol Biol – reference: Guidance for Industry: Development and Licensure of Vaccines to Prevent COVID-19, USFDA, June 2020. – reference: Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 14. June 3, 2021. Available at: – volume: 326 start-page: 35 year: 2021 ident: b0045 article-title: Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial publication-title: JAMA – volume: 593 start-page: 491 year: 2021 ident: b0240 article-title: Mix-and-match COVID vaccines trigger potent immune response publication-title: Nature – reference: Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial. medRxiv – volume: 1131 start-page: 447 year: 2014 end-page: 476 ident: b0150 article-title: Fine epitope mapping based on phage display and extensive mutagenesis of the target antigen publication-title: Methods Mol Biol – volume: 119 start-page: 1 year: 2000 end-page: 3 ident: b0165 article-title: Conjugate vaccines publication-title: Clin Exp Immunol – volume: 595 start-page: 342 year: 2021 end-page: 343 ident: b0070 article-title: COVID vaccines to reach poorest countries in 2023 - despite recent pledges publication-title: Nature – volume: 586 start-page: 589 year: 2020 end-page: 593 ident: b0170 article-title: Jansen, phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: Interim report publication-title: Nature – volume: 596 start-page: 276 year: 2021 end-page: 280 ident: b0225 article-title: Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization publication-title: Nature – volume: 397 start-page: 2461 year: 2021 end-page: 2462 ident: b0215 article-title: Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness publication-title: Lancet – reference: (Consulted October 15, 2021). – volume: 397 start-page: 2043 year: 2021 end-page: 2046 ident: b0245 article-title: Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data publication-title: Lancet – volume: 384 start-page: 2187 year: 2021 end-page: 2201 ident: b0040 article-title: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 publication-title: N Engl J Med – reference: COVID-19 – Landscape of novel coronavirus candidate vaccine development worldwide, September 17, 2021. – reference: (Consulted October 20, 2021). – volume: 397 start-page: 99 year: 2021 end-page: 111 ident: b0025 article-title: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK publication-title: Lancet – volume: 385 start-page: 1172 year: 2021 end-page: 1183 ident: b0060 article-title: Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine publication-title: N Engl J Med DOI – volume: 395 start-page: 1845 year: 2020 end-page: 1854 ident: b0180 article-title: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial publication-title: Lancet – volume: 1 start-page: 769 year: 2021 end-page: 782 ident: b0200 article-title: SARS-CoV-2, COVID-19 and the aging immune system publication-title: Nat Aging – reference: . (consulted October 19, 2021). – volume: 397 start-page: 671 year: 2021 end-page: 681 ident: b0035 article-title: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia publication-title: Lancet – volume: 396 start-page: 479 year: 2020 end-page: 488 ident: b0175 article-title: Immunogenicity and safety of a recombinant adenovirus type-5- vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial publication-title: Lancet – volume: 396 start-page: 467 year: 2020 end-page: 478 ident: b0190 article-title: Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial publication-title: Lancet – volume: 384 start-page: 403 year: 2021 end-page: 416 ident: b0015 article-title: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine publication-title: N Engl J Med – volume: 38 start-page: 1073 year: 2020 end-page: 1078 ident: b0145 article-title: A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction publication-title: Nat Biotechnol – volume: 32 start-page: 5266 year: 2014 end-page: 5270 ident: b0090 article-title: Safety and preliminary immunogenicity of Cuban pneumococcal conjugate vaccine candidate in healthy children: a randomized phase I clinical trial publication-title: Vaccine – reference: International Clinical Trials Registry Platform. Identifier RPCEC00000366. A phase II, sequential, multicenter, adaptive, parallel groups, randomized, placebo-controlled, double-blinded, to evaluate safety, reactogenicity and immunogenicity of the prophylactic vaccine candidate FINLAY-FR-1A anti SARS-CoV-2, in COVID-19 convalescents. – volume: 16 start-page: 1223 year: 2021 end-page: 1233 ident: b0100 article-title: SARS-CoV-2 RBD-Tetanus toxoid conjugate vaccine induces a strong neutralizing immunity publication-title: ACS Chem Biol – volume: 21 start-page: 1107 year: 2021 end-page: 1119 ident: b0135 article-title: Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials publication-title: Lancet Infect Dis – reference: Common Terminology Criteria for Adverse Events (CTCAE): Available: – reference: World Health Organization. Causality Assessment of an Adverse Event Following Immunization (AEFI). 2 – reference: Coronavirus (COVID-19) vaccinations. – volume: 73 start-page: 55 year: 2022 end-page: 64 ident: b0080 article-title: Whole Inactivated Virus and Protein-Based COVID-19 Vaccines publication-title: Annu Rev Med – reference: Chang-Monteagudo A, Ochoa-Azze R, Climent-Ruiz Y, Macías-Abraham C, Rodríguez-Noda L, Valenzuela-Silva C et al. A single dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD recombinant vaccine enhances neutralization response in COVID-19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial. Lancet Reg Health Am 2021;4:100079. – volume: 383 start-page: 2603 year: 2020 end-page: 2615 ident: b0020 article-title: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine publication-title: N Engl J Med – reference: International Clinical Trials Registry Platform. Identifier RPCEC00000347 phase II study, multicenter and adaptive for evaluating the immunogenicity, safety and reactogenicity of the Anti-SARS Prophylactic Vaccine Candidate - CoV - 2, FINLAY- FR-2 (COVID-19). – reference: . – volume: 305 start-page: 522 year: 2004 end-page: 525 ident: b0085 article-title: A synthetic conjugate polysaccharide vaccine against publication-title: Science – volume: 20 start-page: 1201 year: 2021 end-page: 1209 ident: b0210 article-title: Impact of the Delta variant on vaccine efficacy and response strategies publication-title: Expert Rev Vaccines – reference: G. Guzman. Updated report of the “Pedro Kouri” Tropical Medicine Institute on the circulating strains of SARS COVID19 in Havana. Personal communication. – volume: 5 year: 2020 ident: b0230 article-title: SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection publication-title: Sci Immunol – volume: 7 start-page: 757 year: 2021 end-page: 767 ident: b0095 article-title: Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines publication-title: ACS Cent Sci – volume: 398 start-page: 213 year: 2021 end-page: 222 ident: b0050 article-title: Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey“ publication-title: Lancet – reference: International Clinical Trials Registry Platform. Identifier RPCEC00000340. phase I study, open, sequential and adaptive for evaluating the safety, reactogenicity and explore the immunogenicity of the prophylactic Vaccine candidate FINLAY-FR-2 anti SARSCoV-2 (COVID-19). – volume: 383 start-page: 2439 year: 2020 end-page: 2450 ident: b0195 article-title: Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates publication-title: N Engl J Med – volume: 21 start-page: 39 year: 2021 end-page: 51 ident: b0185 article-title: Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial publication-title: Lancet Infect Dis – ident: 10.1016/j.vaccine.2022.05.082_b0120 – volume: 396 start-page: 479 issue: 10249 year: 2020 ident: 10.1016/j.vaccine.2022.05.082_b0175 article-title: Immunogenicity and safety of a recombinant adenovirus type-5- vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial publication-title: Lancet doi: 10.1016/S0140-6736(20)31605-6 – volume: 7 start-page: 757 issue: 5 year: 2021 ident: 10.1016/j.vaccine.2022.05.082_b0095 article-title: Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines publication-title: ACS Cent Sci doi: 10.1021/acscentsci.1c00216 – ident: 10.1016/j.vaccine.2022.05.082_b0105 – volume: 383 start-page: 2439 issue: 25 year: 2020 ident: 10.1016/j.vaccine.2022.05.082_b0195 article-title: Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates publication-title: N Engl J Med doi: 10.1056/NEJMoa2027906 – ident: 10.1016/j.vaccine.2022.05.082_b0110 – volume: 38 start-page: 1073 issue: 9 year: 2020 ident: 10.1016/j.vaccine.2022.05.082_b0145 article-title: A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction publication-title: Nat Biotechnol doi: 10.1038/s41587-020-0631-z – volume: 398 start-page: 213 issue: 10296 year: 2021 ident: 10.1016/j.vaccine.2022.05.082_b0050 article-title: Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey“ publication-title: Lancet doi: 10.1016/S0140-6736(21)01429-X – volume: 396 start-page: 467 issue: 10249 year: 2020 ident: 10.1016/j.vaccine.2022.05.082_b0190 article-title: Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(20)31604-4 – ident: 10.1016/j.vaccine.2022.05.082_b0005 – volume: 305 start-page: 522 issue: 5683 year: 2004 ident: 10.1016/j.vaccine.2022.05.082_b0085 article-title: A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b publication-title: Science doi: 10.1126/science.1095209 – volume: 1 start-page: 769 issue: 9 year: 2021 ident: 10.1016/j.vaccine.2022.05.082_b0200 article-title: SARS-CoV-2, COVID-19 and the aging immune system publication-title: Nat Aging doi: 10.1038/s43587-021-00114-7 – volume: 595 start-page: 342 issue: 7867 year: 2021 ident: 10.1016/j.vaccine.2022.05.082_b0070 article-title: COVID vaccines to reach poorest countries in 2023 - despite recent pledges publication-title: Nature doi: 10.1038/d41586-021-01762-w – volume: 16 start-page: 1223 issue: 7 year: 2021 ident: 10.1016/j.vaccine.2022.05.082_b0100 article-title: SARS-CoV-2 RBD-Tetanus toxoid conjugate vaccine induces a strong neutralizing immunity publication-title: ACS Chem Biol doi: 10.1021/acschembio.1c00272 – volume: 1701 start-page: 535 year: 2018 ident: 10.1016/j.vaccine.2022.05.082_b0155 article-title: Phagekines: screening binding properties and biological activity of functional cytokines displayed on phages publication-title: Methods Mol Biol doi: 10.1007/978-1-4939-7447-4_30 – volume: 397 start-page: 99 issue: 10269 year: 2021 ident: 10.1016/j.vaccine.2022.05.082_b0025 article-title: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK publication-title: Lancet doi: 10.1016/S0140-6736(20)32661-1 – volume: 586 start-page: 589 year: 2020 ident: 10.1016/j.vaccine.2022.05.082_b0170 article-title: Jansen, phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: Interim report publication-title: Nature doi: 10.1038/s41586-020-2639-4 – volume: 73 start-page: 55 issue: 1 year: 2022 ident: 10.1016/j.vaccine.2022.05.082_b0080 article-title: Whole Inactivated Virus and Protein-Based COVID-19 Vaccines publication-title: Annu Rev Med doi: 10.1146/annurev-med-042420-113212 – ident: 10.1016/j.vaccine.2022.05.082_b0125 – volume: 183 start-page: 158 issue: 1 year: 2020 ident: 10.1016/j.vaccine.2022.05.082_b0235 article-title: Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19 publication-title: Cell doi: 10.1016/j.cell.2020.08.017 – ident: 10.1016/j.vaccine.2022.05.082_b0075 – volume: 20 start-page: 1201 issue: 10 year: 2021 ident: 10.1016/j.vaccine.2022.05.082_b0210 article-title: Impact of the Delta variant on vaccine efficacy and response strategies publication-title: Expert Rev Vaccines doi: 10.1080/14760584.2021.1976153 – volume: 596 start-page: 276 issue: 7871 year: 2021 ident: 10.1016/j.vaccine.2022.05.082_b0225 article-title: Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization publication-title: Nature doi: 10.1038/s41586-021-03777-9 – ident: 10.1016/j.vaccine.2022.05.082_b0220 – volume: 1131 start-page: 447 year: 2014 ident: 10.1016/j.vaccine.2022.05.082_b0150 article-title: Fine epitope mapping based on phage display and extensive mutagenesis of the target antigen publication-title: Methods Mol Biol doi: 10.1007/978-1-62703-992-5_27 – ident: 10.1016/j.vaccine.2022.05.082_b0055 doi: 10.1101/2021.06.30.21259439 – ident: 10.1016/j.vaccine.2022.05.082_b0065 – volume: 385 start-page: 1172 issue: 13 year: 2021 ident: 10.1016/j.vaccine.2022.05.082_b0060 article-title: Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine publication-title: N Engl J Med DOI doi: 10.1056/NEJMoa2107659 – volume: 385 start-page: 2348 issue: 25 year: 2021 ident: 10.1016/j.vaccine.2022.05.082_b0030 article-title: Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa2105290 – volume: 326 start-page: 35 issue: 1 year: 2021 ident: 10.1016/j.vaccine.2022.05.082_b0045 article-title: Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial publication-title: JAMA doi: 10.1001/jama.2021.8565 – ident: 10.1016/j.vaccine.2022.05.082_b0115 doi: 10.1016/j.lana.2021.100079 – volume: 21 start-page: 39 issue: 1 year: 2021 ident: 10.1016/j.vaccine.2022.05.082_b0185 article-title: Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(20)30831-8 – volume: 395 start-page: 1845 issue: 10240 year: 2020 ident: 10.1016/j.vaccine.2022.05.082_b0180 article-title: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial publication-title: Lancet doi: 10.1016/S0140-6736(20)31208-3 – volume: 32 start-page: 5266 issue: 41 year: 2014 ident: 10.1016/j.vaccine.2022.05.082_b0090 article-title: Safety and preliminary immunogenicity of Cuban pneumococcal conjugate vaccine candidate in healthy children: a randomized phase I clinical trial publication-title: Vaccine doi: 10.1016/j.vaccine.2014.06.094 – volume: 397 start-page: 2043 issue: 10289 year: 2021 ident: 10.1016/j.vaccine.2022.05.082_b0245 article-title: Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data publication-title: Lancet doi: 10.1016/S0140-6736(21)01115-6 – volume: 593 start-page: 491 issue: 7860 year: 2021 ident: 10.1016/j.vaccine.2022.05.082_b0240 article-title: Mix-and-match COVID vaccines trigger potent immune response publication-title: Nature doi: 10.1038/d41586-021-01359-3 – volume: 384 start-page: 403 issue: 5 year: 2021 ident: 10.1016/j.vaccine.2022.05.082_b0015 article-title: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa2035389 – volume: 397 start-page: 2461 issue: 10293 year: 2021 ident: 10.1016/j.vaccine.2022.05.082_b0215 article-title: Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness publication-title: Lancet doi: 10.1016/S0140-6736(21)01358-1 – ident: 10.1016/j.vaccine.2022.05.082_b0205 – volume: 397 start-page: 671 issue: 10275 year: 2021 ident: 10.1016/j.vaccine.2022.05.082_b0035 article-title: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia publication-title: Lancet doi: 10.1016/S0140-6736(21)00234-8 – volume: 383 start-page: 2603 issue: 27 year: 2020 ident: 10.1016/j.vaccine.2022.05.082_b0020 article-title: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa2034577 – volume: 5 issue: 49 year: 2020 ident: 10.1016/j.vaccine.2022.05.082_b0230 article-title: SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection publication-title: Sci Immunol doi: 10.1126/sciimmunol.abd6160 – ident: 10.1016/j.vaccine.2022.05.082_b0010 – volume: 21 start-page: 1107 issue: 8 year: 2021 ident: 10.1016/j.vaccine.2022.05.082_b0135 article-title: Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(21)00127-4 – volume: 397 start-page: 671 issue: 10275 year: 2021 ident: 10.1016/j.vaccine.2022.05.082_b0140 article-title: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia publication-title: Lancet doi: 10.1016/S0140-6736(21)00234-8 – volume: 384 start-page: 2187 issue: 23 year: 2021 ident: 10.1016/j.vaccine.2022.05.082_b0040 article-title: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2101544 – volume: 119 start-page: 1 issue: 1 year: 2000 ident: 10.1016/j.vaccine.2022.05.082_b0165 article-title: Conjugate vaccines publication-title: Clin Exp Immunol doi: 10.1046/j.1365-2249.2000.01109.x – volume: 92 start-page: 2096 issue: 10 year: 2020 ident: 10.1016/j.vaccine.2022.05.082_b0160 article-title: Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples publication-title: J Med Virol doi: 10.1002/jmv.25986 – ident: 10.1016/j.vaccine.2022.05.082_b0130 |
| SSID | ssj0005319 |
| Score | 2.536298 |
| Snippet | SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we report... AbstractBackgroundSOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is... BackgroundSOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here... |
| SourceID | unpaywall pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 4220 |
| SubjectTerms | Adult Aged Aged, 80 and over Allergy and Immunology Antibodies Antibodies, Neutralizing Antibodies, Viral Antigens blood serum Clinical medicine Clinical trials Conjugate vaccine Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 - therapy COVID-19 infection COVID-19 Serotherapy COVID-19 vaccines COVID-19 Vaccines - adverse effects Enzyme-linked immunosorbent assay Heterologous immunization scheme Homology Humans Immune response Immune system Immunization, Passive Immunogenicity Immunogenicity, Vaccine Immunoglobulin G Immunology Laboratory animals Lymphocytes T Middle Aged Neutralization pain Proteins Safety SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Subunit vaccine T-lymphocytes Tetanus Vaccines Young Adult |
| SummonAdditionalLinks | – databaseName: ScienceDirect (Elsevier) dbid: .~1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3batswVJTCLi-jy25Zu6HB6FOdyJJ821sWWtrButK0JW9CtmXiktqhTjbyst_Y7-4c39KQbS17i6VzkC0dnUvOjZCPMuDGBkKwYiEcSyaetjQLfUt7SRz4IsLIC4y2OHWPL-WXsTPeIsMmFwbDKmveX_H0klvXI_16N_uzNO2PWCnL2Zjz0peMNUGl9LCLQe_nnTAPUTb3QGALoVdZPP3r3ncdofsazETOywKePv-bfNrUPzfDKJ8ssple_tDT6R0ZdbRDntXKJR1U7_-cbJmsQx5V7SaXHfL4a-1I75D9s6pk9fKAXqwysIoDuk_PVsWsAadzhfEyZdIubdBfkF8jnZj5kuospilmmORAhzAHQ3kCo_PUGg3OR3SYX1mc1t9PR98-H54PTgeUcZpmdJLf4CL5oqD5LZ3gOs0zmNzmxnyiGO5CgU7NlM4mIG_pSblk_ftE0yaxk5bdR4qX5PLo8GJ4bNUtHqzIFd7ccjzm-GiywAEIoKbIDdARycKYeWBI2hEoHEbEOpI81FLHnkhCE8tEG5b4oZ2IV2Q7yzPzhlDDQdhq48VJgDXwZGhsAHW1SSQMc6dLZHOwKqrrn2MbjqlqAt2uVb0fCulBMUcBPXRJr0WbVQVA7kNwG6pRzSYAP1Ygou5D9P6EaIqaqxTKVgUAqw3K7xK_xVy7PA9ZdK8hbNWuw6sOmdJnXfKhnQa-g84knRkgBIRxAl9KFvwDBhQfLgJb2l3yuror7R4Kxw1ssNbhq9duUQuAdc_XZ7J0UtY_B4vG8wVg9tv79rCjefv_-7RLnuIT_qvPgz2yPb9dmHegjs7D9yW_-Q2TWIlP priority: 102 providerName: Elsevier – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3rb9MwELemTTy-8CivwEBGQvu0pI7tvPhWpk0bEqVq16l8spzEUTvapFpSUPlH-Hc551XGgG3fGp9PVpw73139uzuE3vGAKhsEwYwZc0yeeNKUJPRN6SVx4LNIIy802qLvHo_5x4kz2UJ2kwtTgvajcGal84WVzqYltnK5iLoNTqwL_ozn68zpHdcB93sb7Yz7g96X6r8UbnKbTHSQ5XvMBNvtb7J2uufWNxnp62oICyktC3b69F_26Kq_eRU2eW-VLuX6u5zPf7NJRw_RsHmbCory1VoVoRX9-KPQ461e9xF6UHuouFeRHqMtlXbQnapn5bqD7n6qb-M7aG9Q1b1e7-PTTRpXvo_38GBTERt4OmcadFNm_uKG_Qn6OZKJKtZYpjGe6TSVDIQZaDCUJTBazMxRbzjCB9mZSXG9qXj0-cPhsNfvYULxLMXTbKEXyVY5zi7wVK_TPEPcrhbqPdaYGQzCruZ4OQWjjU_KJevfJxI32aG4bGGSP0Xjo8PTg2Oz7hNhRi7zCtPxiOPruAe-KgORjNxA32aSMCYeRKN2BF6LYrGMOA0ll7HHklDFPJGKJH5oJ-wZ2k6zVL1AWFGw2FJ5cRLoQno8VDZMdaVKOAxTx0C8kRYR1UXUdS-PuWjQcuei3g-hhUwQR4CQGchq2ZZVFZHrGNxGFEWzCXCoC7Bz1zF6f2NUeX005cIWOUwWI1K6wmRCaQnF4AbyW87a-6q8qpssuttoi2jXoVWbTe4TA71tyXB46RspmSoQBD3HCXzOSfCfOeA9URbY3DbQ80oB2z1kjhuApgPFu6Sa7QRdPP0yBZSsLKJe65WBuq0S3-zTvLw1xyt0Xz_pGwEa7KLt4mKlXoMrW4Rv6sPrF96_noA priority: 102 providerName: Unpaywall |
| Title | Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X22007174 https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X22007174 https://dx.doi.org/10.1016/j.vaccine.2022.05.082 https://www.ncbi.nlm.nih.gov/pubmed/35691871 https://www.proquest.com/docview/2676930480 https://www.proquest.com/docview/2675984409 https://www.proquest.com/docview/2718239141 https://pubmed.ncbi.nlm.nih.gov/PMC9167831 https://www.ncbi.nlm.nih.gov/pmc/articles/9167831 |
| UnpaywallVersion | submittedVersion |
| Volume | 40 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier Science Direct Complete Freedom Collection customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: ACRLP dateStart: 20091030 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: AIKHN dateStart: 20091030 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect (Elsevier) customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: AKRWK dateStart: 19831201 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1873-2518 dateEnd: 20250902 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 7X7 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1873-2518 dateEnd: 20250902 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: BENPR dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1873-2518 dateEnd: 20250902 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 8C1 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR1rb9Mw0Npa8fiCoLwKYzIS2qdldRznhYRQVnVqQYSqXafyyXISR-3UJWVpQf3C3-Dvcs6rTINtX_Kw72LZPp_v4nsg9I65VOpACFpkGKbGYltoggSOJuw4ch0jVJYXytrCt_oT9mlqTneQX_nCKLPKiifmjDpKQ_WPvEOLrH3MIR-X3zWVNUqdrlYpNESZWiH6kIcY20VNqiJjNVDzuOcPR1ujDyNP9QGKB9OYTqZbn57O-dEP-AqIdqA0UpqH83To_3ar69LodaPKB-tkKTY_xWLx14518hg9KkVN7BW08QTtyKSF7hXJJzctdP9LeazeQgfDIoD15hCfbv2xskN8gIfb0NaA0zpT1jO5Cy-u0J-i32MRy9UGiyTCc-VvkgJVQh0UpTGUruba2BuNcTc90ygu-4_HX497I8_3MKF4nuBZeqEaSdcZTi_xTLVTvYMCLi_ke6yMXzBQrVzg5Qx2XzzImyyfBwJXbp44z0WSPUOTk95pt6-VCR-00DLslWbaxHSUAgMTYABthZarjiVJEBEb1Eo9BPFDGpEIGQ0EE5FtxIGMWCwkiZ1Aj43nqJGkiXyJsKSw9QppR7GrIuKxQOoAagkZMyimZhuxamJ5WEZDV0k5Frwyezvn5XhwRQ-cmBzooY2OarRlEQ7kNgSrohpeDQJwZw4b1m2I9r8QZVbymIzrPANgPia5TEumlOY2FayNnBqzFKMK8eguje5VhM3rdrYrr43e1tXAhdTRkkgkEIKCMV2HMeLeAANiEDVcnelt9KJYK_UYGqbl6qC7Q6-vrKIaQEVBv1qTzGd5NHTQb2zHAMxOvd7uNjWvbu7sa_RQAav_-NTdQ43V5Vq-AQF0Feyj3aNfOlztqQ1XpwvPTW_wue_vl_wG7hN_6H37A1wZi6s |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1BqbYLwgKLfCACPBnpbVsZ0mQZpQNzq1bCtV2019M07iqJ26pCwtU7-Ev-HbOM6tTINtL3tLbZ-4ts81PheEPnCXKhMQwQgYswwe2tKQxHMMaYeB6zBfe15ob4tOvXXMvw6t4Qr6XcTCaLfKgiemjDqIff2NvEazqn3cIZ-nPwxdNUrfrhYlNGReWiHYSVOM5YEdB2pxASZcstP-Auf9kdL95mCvZeRVBgy_zuyZYdnEcrTWDNKMwYL8uqvvwogXEBtsGdMHmadYIH1OPcllYLPQUwEPpSKh45khg_feQ2uccReMv7XdZqfbWzqZsLS0CBg63OAmGS5jiGqn2z_hX4MqCUYqpWn6UIf-Tzpe1X6vOnGuz6OpXFzIyeQvCbn_GD3KVVvcyHDxCVpRUQXdz4pdLirowVF-jV9Bm90sYfZiCw-W8V_JFt7E3WUqbYCpnGhvnTRkGBfgT9GvvgzVbIFlFOCxjm-JgQqgD5riEFpnY6Pf6PXxXnxiUJyvH_e_7TZ7jU4DE4rHER7FZ3qSeJ7g-ByP9DzFbzD41Zn6hLWzDQYqURM8HYG0x-10yvy5LXERVorT2ifJM3R8J0f_HK1GcaReIqwoiHqp7CB0dQY-7ikThtalCjk0U6uKeHGwws-zr-siIBNRuNmdinw_hMYHQSwB-FBF2yXYNEs_chNAvcAaUWwCSAMBAvImQPtfgCrJeVoiTJHAYNEnqQ5NhpSmPhy8ipwSMlfbMnXsNpNuFIgtynmWlF5F78tu4Hr6KktGChBBj7Fch3PiXjMG1C7KXJObVfQio5VyD5lVd03Hhh77EhWVA3TW9cs90XiUZl8He8p2GEDWSnq73dG8un6x79B6a3B0KA7bnYPX6KEG1HcI1N1Aq7PzuXoDyu_Me5tzGIy-3zVT-wPI5sLP |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1BpDDF4QlFthgJFgT8vq2E6cICFUtlUrgzKt29Q34ySO2qlLytIy9Uv4F76O49zKNNj2srfW9umR7eNz6bkh9Jb7VNtACFbEmGPxWChLkcCzlIgj32Ohibww0RY9d-eQfx44gyX0u8qFMWGVFU_MGXWUhuY_8hYtuvZxj7TiMixib6vzcfLDMh2kjKe1aqdRkMiunp-B-ZZ96G7BXb-jtLN9sLljlR0GrNBlYmo5gjie0ZhBkjHYTOj6xg9GgogIsGPsEOSdZpEKOQ0UV5FgcaAjHitNYi-wYwa_ewvdFoz5JpxQDMQivITlTUXAxOEWt8lgkT3UOt74qULjNgfzlNK8cKhH_ycXL-q9F8M3786SiZqfqfH4L9nYeYDul0otbhdU-BAt6aSB7hRtLucNtPK1dOA30NpeUSp7vo4PFplf2Tpew3uLItoA0zgycTp5sjCuwB-hX30V6-kcqyTCI5PZkgL9wxwMpTGMTkdWv73fx5vpkUVxuX_c__Zpe7_da2NC8SjBw_TEIElnGU5P8dDgqb6Dqa9P9HtswmwwvA89xpMhyHnczVGWn7sKVwmlOO96kj1Ghzdy8U_QcpIm-hnCmoKQV1pEsW9q7_FA27DUVTrmMEydJuLVxcqwrLtu2n-MZRVgdyzL85CGHiRxJNBDE23UYJOi8MhVAG5FNbI6BJADEkTjVYDiX4A6K7lZJm2ZwWLZJ7n2TAaU5tEbvIm8GrJU2ApF7DpIVyvCljWexRtvojf1NPA748RSiQZCMGsc3-Oc-JesAYWLMt_mdhM9Ld5KfYbMcX3bEzAjzr2ieoGpt35-JhkN87rrYEkJjwFkq35v17ua55dv9jVaAVYmv3R7uy_QPQNnnAfUX0XL09OZfgla7zR4lbMXjL7fND_7A3Z4wGk |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3rb9MwELemTTy-8CivwEBGQvu0pI7tvPhWpk0bEqVq16l8spzEUTvapFpSUPlH-Hc551XGgG3fGp9PVpw73139uzuE3vGAKhsEwYwZc0yeeNKUJPRN6SVx4LNIIy802qLvHo_5x4kz2UJ2kwtTgvajcGal84WVzqYltnK5iLoNTqwL_ozn68zpHdcB93sb7Yz7g96X6r8UbnKbTHSQ5XvMBNvtb7J2uufWNxnp62oICyktC3b69F_26Kq_eRU2eW-VLuX6u5zPf7NJRw_RsHmbCory1VoVoRX9-KPQ461e9xF6UHuouFeRHqMtlXbQnapn5bqD7n6qb-M7aG9Q1b1e7-PTTRpXvo_38GBTERt4OmcadFNm_uKG_Qn6OZKJKtZYpjGe6TSVDIQZaDCUJTBazMxRbzjCB9mZSXG9qXj0-cPhsNfvYULxLMXTbKEXyVY5zi7wVK_TPEPcrhbqPdaYGQzCruZ4OQWjjU_KJevfJxI32aG4bGGSP0Xjo8PTg2Oz7hNhRi7zCtPxiOPruAe-KgORjNxA32aSMCYeRKN2BF6LYrGMOA0ll7HHklDFPJGKJH5oJ-wZ2k6zVL1AWFGw2FJ5cRLoQno8VDZMdaVKOAxTx0C8kRYR1UXUdS-PuWjQcuei3g-hhUwQR4CQGchq2ZZVFZHrGNxGFEWzCXCoC7Bz1zF6f2NUeX005cIWOUwWI1K6wmRCaQnF4AbyW87a-6q8qpssuttoi2jXoVWbTe4TA71tyXB46RspmSoQBD3HCXzOSfCfOeA9URbY3DbQ80oB2z1kjhuApgPFu6Sa7QRdPP0yBZSsLKJe65WBuq0S3-zTvLw1xyt0Xz_pGwEa7KLt4mKlXoMrW4Rv6sPrF96_noA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+and+immunogenicity+of+anti-SARS+CoV-2+vaccine+SOBERANA+02+in+homologous+or+heterologous+scheme%3A+Open+label+phase+I+and+phase+IIa+clinical+trials&rft.jtitle=Vaccine&rft.au=Eugenia-Toledo-Roman%C3%AD%2C+Mar%C3%ADa&rft.au=Verdecia-S%C3%A1nchez%2C+Leslyhana&rft.au=Rodr%C3%ADguez-Gonz%C3%A1lez%2C+Meiby&rft.au=Rodr%C3%ADguez-Noda%2C+Laura&rft.date=2022-07-29&rft.pub=Elsevier+Limited&rft.issn=0264-410X&rft.eissn=1873-2518&rft.volume=40&rft.issue=31&rft.spage=4220&rft_id=info:doi/10.1016%2Fj.vaccine.2022.05.082&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0264-410X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0264-410X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0264-410X&client=summon |